Shares of Cytokinetics (NASDAQ: CYTK) are up 48.4% as of 12:00 p.m. EDT on Monday. Investors were caught off guard by some encouraging results from a clinical trial with CK-274, a potential new treatment for hypertrophic cardiomyopathy (HCM).
Patients with HCM have heart muscle that becomes thicker, which can cause it to pump with too much force. Today, Cytokinetics showed us clear signs that CK-274, an oral cardiac myosin inhibitor, can safely get the hearts of HCM patients to relax.
Image source: Getty Images.
For further details see:
Here's Why Cytokinetics Is Rocketing Higher Today